The Clinical Potential of Senolytic Drugs

James L. Kirkland, Tamara Tchkonia, Yi Zhu, Laura J. Niedernhofer, Paul D. Robbins

Research output: Contribution to journalArticlepeer-review

213 Scopus citations

Abstract

Senolytic drugs are agents that selectively induce apoptosis of senescent cells. These cells accumulate in many tissues with aging and at sites of pathology in multiple chronic diseases. In studies in animals, targeting senescent cells using genetic or pharmacological approaches delays, prevents, or alleviates multiple age-related phenotypes, chronic diseases, geriatric syndromes, and loss of physiological resilience. Among the chronic conditions successfully treated by depleting senescent cells in preclinical studies are frailty, cardiac dysfunction, vascular hyporeactivity and calcification, diabetes mellitus, liver steatosis, osteoporosis, vertebral disk degeneration, pulmonary fibrosis, and radiation-induced damage. Senolytic agents are being tested in proof-of-concept clinical trials. To do so, new clinical trial paradigms for testing senolytics and other agents that target fundamental aging mechanisms are being developed, because use of long-term endpoints such as lifespan or healthspan is not feasible. These strategies include testing effects on multimorbidity, accelerated aging-like conditions, diseases with localized accumulation of senescent cells, potentially fatal diseases associated with senescent cell accumulation, age-related loss of physiological resilience, and frailty. If senolytics or other interventions that target fundamental aging processes prove to be effective and safe in clinical trials, they could transform geriatric medicine by enabling prevention or treatment of multiple diseases and functional deficits in parallel, instead of one at a time.

Original languageEnglish (US)
Pages (from-to)2297-2301
Number of pages5
JournalJournal of the American Geriatrics Society
Volume65
Issue number10
DOIs
StatePublished - Oct 2017
Externally publishedYes

Bibliographical note

Funding Information:
The authors appreciate the assistance of Jaqueline Armstrong. This work was funded by National Institutes of Health Grants AG013925, AG044396, and AG043376; the American Federation for Aging Research; Aldabra Biosciences; the Connor Group; and the Noaber, Glenn, and Ted Nash Foundations.

Keywords

  • SCAPs
  • cellular senescence
  • chronic diseases
  • geroscience hypothesis
  • senolytics

Fingerprint

Dive into the research topics of 'The Clinical Potential of Senolytic Drugs'. Together they form a unique fingerprint.

Cite this